What medical problems did the participants have during this study?
This section is a summary of the medical problems the participants had during the study that the study doctors thought might be related to acalabrutinib. These medical problems are called "adverse reactions". An adverse reaction is considered "serious" when it is life-threatening, causes lasting problems, or requires hospital care.
These adverse reactions may or may not be caused by acalabrutinib. A lot of research is needed to know whether a drug causes an adverse reaction. These adverse reactions have been, and will continue to be, reviewed together with all of the available data for acalabrutinib.
The websites listed at the end of this summary may have other information about adverse reactions or other medical problems that happened during this study.
This summary does not include adverse reactions for the participants who took BSC only. There were 3 participants who were planned to take acalabrutinib and BSC, but these participants did not take any acalabrutinib. So, the results below are only for the 86 participants who took acalabrutinib and BSC.
Did any adverse reactions happen during this study?
There were 15.1% of participants who took acalabrutinib and BSC who had adverse reactions. This was 13 out of 86 participants.
There were 3.5% of participants who took acalabrutinib and BSC who stopped taking study treatment due to adverse reactions. This was 3 out of 86 participants.
What serious adverse reactions happened during this study?
There were 2.3% of participants who took acalabrutinib and BSC who had 1 serious adverse reaction each. This was 2 out of 86 participants. These serious adverse reactions were pneumonia and an infection in the moist inner lining of a body cavity such as the nose, mouth, lungs, or stomach.
There were 1.2% of participants who died due to a serious adverse reaction. This was 1 out of 86 participants. This serious adverse reaction was pneumonia.